Pharscin Pharma(SZ:002907)2025-09-09 08:10Financial Performance - In the first half of 2025, the company achieved a revenue of CNY 442 million, an increase of 5.76% compared to the same period last year [3] - The net profit attributable to shareholders reached CNY 53.95 million, up 14.27% year-on-year [3] - The basic and diluted earnings per share increased by 14.24% compared to the previous year [3] Key Growth Drivers - Revenue growth was driven by a 29.45% increase in revenue from approved generic drugs and successful bidding in centralized procurement [3] - Steady growth in the revenue of five key traditional Chinese medicine products, which increased by 3.52% year-on-year [3] - Cost control measures and a decrease in raw material prices contributed to profit growth [3] Research and Development - R&D investment in the first half of 2025 was CNY 40.50 million, a year-on-year increase of 29.33%, accounting for 9.17% of revenue [7] - The company has 7 innovative drug projects in the pipeline, targeting various cancers and autoimmune diseases [8] - A total of 8 new compound patents were applied for in the first half of 2025, with 3 granted [8] Product Development and Market Strategy - The company has four self-developed special medical foods, with the first product receiving regulatory approval [9] - The sales strategy remains stable, focusing on public hospitals, which account for approximately 70% of sales [12][13] - The company is expanding its market presence through digital marketing and e-commerce platforms [9] Shareholder Returns - The company distributed CNY 0.35 per 10 shares to shareholders, totaling CNY 14.62 million [14] - The profit distribution plan was approved and implemented in September 2025 [14] Governance and Internal Control - The company has established a comprehensive internal control system, which has been positively evaluated by external auditors [11][15] - Continuous improvements to governance structures and compliance with legal regulations are prioritized [15]